Leon Kircik, MD discusses the potential role of emerging AD treatments, including:
Why has atopic dermatitis lagged behind compared to psoriasis in terms of approved targeted treatments? What are some of the most promising therapies that will likely be part of the AD treatment table in the near future? Do you foresee that they will be also approved for pediatric AD, or only for the adult population? In terms of assessing disease severity, how practical are the scales used in clinical trials? Should we put more emphasis on patient-reported outcomes?